Brief: Inhibikase Therapeutics Announces Advancement Of Ikt-148009 Phase 2 '201' Program Following FDA Review
13/06/2022 13:14
June 13 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES ADVANCEMENT OF
IKT-148009
PHASE 2 '201' PROGRAM FOLLOWING FDA REVIEW
* INHIBIKASE THERAPEUTICS INC- PHASE 1/1B '101' STUDY
TERMINATED
EARLY; DEMONSTRATED FAVORABLE SAFETY, TOLERABILITY
* INHIBIKASE THERAPEUTICS INC- PHASE 2A '201' STUDY OPEN FOR
ENROLLMENT; EXPECT TO DOSE FIRST PATIENT IN 2Q 2022
* INHIBIKASE THERAPEUTICS INC - PHASE 1/1B '101' STUDY
TERMINATED
EARLY
Source text for Eikon: ID:nPn77Zsxga
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary